FDA approves Merck's oral PCSK9 inhibitor Lipfendra to lower LDL cholesterol
The U.S. Food and Drug Administration has approved enlicitide, sold under the brand name Lipfendra, as the first oral inhibitor of the PCSK9 protein. Developed by Merck & Co (MSD), the once‑daily tablet is intended for adults with hypercholesterolemia, including those with heterozygous familial high cholesterol. Clinical trials showed the drug cut low‑density lipoprotein (LDL) cholesterol by roughly 56‑60 % after 24 weeks, matching the efficacy of existing injectable PCSK9 inhibitors.
The approval expands treatment options beyond statins and injectable biologics, which cost $500‑$600 per month. Lipfendra’s list price is set at $315 for a 30‑day supply, a potential catalyst for wider patient adherence. Cardiovascular disease remains the leading cause of death in the United States, accounting for about one‑fifth of all deaths, and the new oral therapy could affect millions of high‑risk patients.
The FDA’s decision follows data from more than 19,000 participants who were already on statins and lifestyle measures, showing a favorable safety profile with few side effects. The drug may later be evaluated by health regulators in other markets, such as Brazil’s ANVISA.
Entities: Lipfendra (enlicitide) · Merck & Co (MSD) · Michael Davis · PCSK9 protein · U.S. Food and Drug Administration
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Only about 1 % of the roughly six million eligible patients in the U.S. currently use injectable PCSK9 inhibitors.
- [● 4 SOURCES] Lipfendra is marketed by Merck (MSD).
- [● 2 SOURCES] The FDA approved the drug for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
- [○ 1 SOURCE] Lipfendra’s list price is $315 for a 30‑day supply, cheaper than injectable PCSK9 inhibitors priced $500‑$600 per month.
- [● 4 SOURCES] The FDA approved enlicitide, the first oral PCSK9 inhibitor, under the brand name Lipfendra. (a521c6b5-282b-41fc-bc6c-501153b4d97a, 8ac3ee04-3ef5-477a-9629-12a1a5039fc5, ab3f9f3c-f732-4fc8-9b8b-a178806d485f, c699e3)
- [○ 1 SOURCE] Cardiovascular disease is the leading cause of death in the United States, causing about 694,708 deaths in 2025.
- [● 2 SOURCES] The pill is taken once daily on an empty stomach.
- [● 4 SOURCES] Enlicitide lowers LDL cholesterol by approximately 56 % to 60 % in clinical trials.